Skip to main content
. 2023 Dec 5;23:1190. doi: 10.1186/s12885-023-11693-6

Table 2.

Long-term outcomes after resection relative to PACE risk score

Variable Total PACE low-risk PACE intermediate-risk PACE high-risk P
Median RFS, months 37.4 (35.0, 42.2) 47.5 (43.5, 57.3) 27.8 (24.8, 34.3) 7.7 (6.0, 10.8) < 0.001 *
1-year RFS 72.0 (70.4, 73.8) 79.1 (77.2, 81.1) 64.4 (61.4, 67.6) 40.0 (32.5, 49.1)
3-year RFS 51.5 (49.4, 53.6) 57.3 (54.7, 60.0) 45.5 (42.0, 49.1) 23.0 (162, 32.7)
5-year RFS 41.2 (38.6, 43.9) 44.9 (41.5, 48.5) 38.4 (34.4, 43.0) 18.0 (11.5, 28.3)
Recurrence, n, % 1272 (45.9%) 684 (41.1%) 485 (50.6%) 103 (70.1%) < 0.001 #
Recurrence Timing
Early recurrence, ≤ 24 months 998 (78.5%) 502 (73.4%) 403 (82.2%) 93 (90.3%) < 0.001 #
Late recurrence, > 24 months 274 (21.5%) 182 (26.6%) 82 (17.8%) 10 (9.7%)
Recurrence pattern
Intrahepatic 1052 (82.7%) 592 (86.5%) 376 (77.5%) 84 (81.6%) 0.001 #
Extrahepatic 72 (5.7%) 25 (3.7%) 40 (8.3%) 7 (6.8%)
Both 148 (11.6%) 67 (9.8%) 69 (14.2%) 12 (11.6%)
Death, n, % 947 (34.2%) 464 (27.9%) 387 (40.4%) 96 (65.3%) < 0.001 #
Median OS, months 60.4 (59.4, 61.1) 65.5 (61.3, 75.4) 48.7 (48.1, 59.2) 19.9 (14.7, 26.6) < 0.001 *
1-year OS 89.7 (88.6, 90.9) 93.5 (92.3, 94.7) 86.4 (84.3,88.7) 68.8 (61.6, 76.9)
3-year OS 68.2 (66.2, 70.1) 76.3 (74.0, 78.6) 59.5 (56.0, 63.1) 32.5 (24.9, 42.4)
5-year OS 52.1 (49.4, 54.9) 59.6 (56.1, 63.2) 43.9 (39.2, 49.0) 20.6 (13.5, 31.5)

Abbreviations: PACE, Prognostic implications of Alpha-fetoprotein and C-reactive protein Elevation; RFS, recurrence-free survival; OS, overall survival

*Tested by log-rank test; #Tested by χ2 test